[go: up one dir, main page]

DE60117978D1 - Modifizierung des hepatitis b kernantigens - Google Patents

Modifizierung des hepatitis b kernantigens

Info

Publication number
DE60117978D1
DE60117978D1 DE60117978T DE60117978T DE60117978D1 DE 60117978 D1 DE60117978 D1 DE 60117978D1 DE 60117978 T DE60117978 T DE 60117978T DE 60117978 T DE60117978 T DE 60117978T DE 60117978 D1 DE60117978 D1 DE 60117978D1
Authority
DE
Germany
Prior art keywords
hepatitis
hbcag
protein
nuclear
modifying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60117978T
Other languages
English (en)
Other versions
DE60117978T2 (de
Inventor
Mark Page
Jing-Li Li
Paul Pumpens
Galina Borisova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma Ltd
Original Assignee
UCB Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0015308A external-priority patent/GB0015308D0/en
Priority claimed from GB0024544A external-priority patent/GB0024544D0/en
Application filed by UCB Pharma Ltd filed Critical UCB Pharma Ltd
Publication of DE60117978D1 publication Critical patent/DE60117978D1/de
Application granted granted Critical
Publication of DE60117978T2 publication Critical patent/DE60117978T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60117978T 2000-06-22 2001-06-22 Modifizierung des hepatitis b kernantigens Expired - Lifetime DE60117978T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0015308A GB0015308D0 (en) 2000-06-22 2000-06-22 Modification of hepatitis B core antigen
GB0015308 2000-06-22
GB0024544A GB0024544D0 (en) 2000-10-06 2000-10-06 Modification of hepatitus B core antigen
GB0024544 2000-10-06
PCT/GB2001/002817 WO2001098333A2 (en) 2000-06-22 2001-06-22 Modification of hepatitis b core antigen

Publications (2)

Publication Number Publication Date
DE60117978D1 true DE60117978D1 (de) 2006-05-11
DE60117978T2 DE60117978T2 (de) 2006-11-02

Family

ID=26244528

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60117978T Expired - Lifetime DE60117978T2 (de) 2000-06-22 2001-06-22 Modifizierung des hepatitis b kernantigens

Country Status (11)

Country Link
US (1) US20040054139A1 (de)
EP (1) EP1294893B1 (de)
JP (1) JP2004500868A (de)
AT (1) ATE320493T1 (de)
AU (2) AU6616301A (de)
CA (1) CA2413546C (de)
DE (1) DE60117978T2 (de)
DK (1) DK1294893T3 (de)
ES (1) ES2260235T3 (de)
PT (1) PT1294893E (de)
WO (1) WO2001098333A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027281A1 (en) * 1999-10-08 2001-04-19 Celltech Pharma Europe Limited Designing immunogens
US7270821B2 (en) * 2000-04-07 2007-09-18 University Of Leeds Innovations Limited Hepatitis B core antigen fusion proteins
US6942866B2 (en) 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
CU23002A1 (es) * 2000-12-01 2004-11-18 Ct Ingenieria Genetica Biotech Método de obtención de agregados antigénicos y su uso en formulaciones
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US20030202982A1 (en) * 2001-08-15 2003-10-30 Birkett Ashley J. Influenza immunogen and vaccine
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US20040146524A1 (en) * 2002-02-21 2004-07-29 Katelynne Lyons Stabilized immunogenic HBc chimer particles
CN1599623B (zh) 2001-09-14 2011-05-11 赛托斯生物技术公司 免疫刺激物向病毒样颗粒内的包装:制备方法与用途
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
BR0213117A (pt) 2001-10-05 2004-09-21 Cytos Biotechnology Ag Conjugados peptìdeo angiotensina-veìculo e seus usos
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
AU2003215395A1 (en) * 2002-02-21 2003-09-09 Apovia, Inc. STABILIZED HBc CHIMER PARTICLES HAVING MENINGOCCOCAL IMMUNOGENS
AU2003250106B2 (en) 2002-07-18 2009-11-26 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
PL217409B1 (pl) 2002-07-19 2014-07-31 Cytos Biotechnology Ag Kompozycja, kompozycja farmaceutyczna i kompozycje szczepionki zawierające układ antygenowy amyloidu beta 1-6 oraz sposób ich wytwarzania i zastosowanie
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
US7517520B2 (en) 2003-03-26 2009-04-14 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
AU2004260665B2 (en) * 2003-07-30 2007-11-15 Vlp Biotech, Inc. Hepatitis virus core proteins as vaccine platforms and methods of use thereof
US7144712B2 (en) * 2003-07-30 2006-12-05 Vaccine Research Institute Of San Diego Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
US7320795B2 (en) * 2003-07-30 2008-01-22 Vaccine Research Institute Of San Diego Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
US20050175583A1 (en) * 2003-12-02 2005-08-11 Lawrence Tamarkin Methods and compositions for the production of monoclonal antibodies
EP1764369A1 (de) 2005-09-16 2007-03-21 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
US7960145B2 (en) * 2007-11-08 2011-06-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
KR101634058B1 (ko) 2008-12-09 2016-06-27 화이자 백신스 엘엘씨 ＩｇＥ ＣＨ３ 펩티드 백신
CA2768346A1 (en) 2009-07-30 2011-02-03 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
KR101660578B1 (ko) 2009-09-03 2016-09-27 화이자 백신스 엘엘씨 Ｐｃｓｋ９ 백신
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
JP6057296B2 (ja) * 2011-04-15 2017-01-11 国立大学法人大阪大学 Ｄｎａワクチン
JP6422022B2 (ja) * 2012-08-31 2018-11-14 国立大学法人大阪大学 Ｖｅｇｆ及び／又はアンギオポエチン−２の特異的エピトープを含むｄｎａワクチン
JP6001974B2 (ja) 2012-09-21 2016-10-05 アンジェスＭｇ株式会社 アポリポプロテイン（ａ）の特異的エピトープを含むＤＮＡワクチン
CN104341506A (zh) * 2013-07-30 2015-02-11 复旦大学 一种重组融合蛋白及其用途
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
JPWO2015133467A1 (ja) * 2014-03-06 2017-04-06 株式会社シノテスト Ｃ型肝炎ウイルスのワクチン及び診断に用いるためのＨＢｃ／ＨＣＶ Ｅ２ペプチドキメラタンパク質
CA3092935A1 (en) 2018-03-06 2019-09-12 Precigen, Inc. Hepatitis b vaccines and uses of the same
US10907161B2 (en) 2018-04-19 2021-02-02 Checkmate Pharmaceuticals, Inc. Synthetic RIG-I-like receptor agonists
JP7491932B2 (ja) * 2018-12-28 2024-05-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 操作されたｂ型肝炎コアポリペプチド
PH12022550490A1 (en) * 2019-08-29 2023-02-06 Triad Nat Security Llc Hepatitis b virus vaccines
JP7398556B2 (ja) 2019-09-30 2023-12-14 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖワクチン及びｈｂｖを治療する方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235315A (en) * 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
WO2000026385A1 (en) * 1998-11-05 2000-05-11 Powderject Vaccines, Inc. Nucleic acid constructs for genetic immunization

Also Published As

Publication number Publication date
WO2001098333A2 (en) 2001-12-27
JP2004500868A (ja) 2004-01-15
ES2260235T3 (es) 2006-11-01
AU2001266163B2 (en) 2006-07-13
EP1294893A2 (de) 2003-03-26
CA2413546C (en) 2011-06-14
DK1294893T3 (da) 2006-07-03
ATE320493T1 (de) 2006-04-15
CA2413546A1 (en) 2001-12-27
US20040054139A1 (en) 2004-03-18
AU6616301A (en) 2002-01-02
PT1294893E (pt) 2006-08-31
EP1294893B1 (de) 2006-03-15
DE60117978T2 (de) 2006-11-02
WO2001098333A3 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
DE60117978D1 (de) Modifizierung des hepatitis b kernantigens
DE60039715D1 (de) Hcv-impfstoff zusammensetzungen
DK1362109T3 (da) Rekombinante oligomere protein-komplekser med foröget immunogent potentiale
ES2109921T3 (es) Nuevos antigenos y procedimientos para su preparacion.
ATE323758T1 (de) Attenuierte lebendimpfstoffe
EA200201077A1 (ru) Коровые антигенные химерные белки гепатита в
NZ545048A (en) Chimeric antigens for breaking host tolerance to foreign antigens
EA200300129A1 (ru) Очистка антигенов вируса гепатита b (hbv) для применения в вакцинах
AP2002002685A0 (en) Use of flavivirus for the expression of protein epitpoes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents
DK1283887T3 (da) Kimære Arterivirus-lignende partikler
SG144692A1 (en) Antigenic proteins of shrimp white spot syndrome virus and uses thereof
WO2002013855A3 (en) Vaccines containing ribavirin and methods of use thereof
DK1035133T3 (da) Fusionsproteiner, der omfatter bærere, som kan inducere et dobbelt immunrespons
AU5573196A (en) A pluripotent vaccine against enveloped viruses
ATE283066T1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
HK1052368A1 (zh) 具有源於肝炎e病毒orf2的n末端部分及一抗原多肽加工的編碼成份的核酸結構
NO20041564L (no) Infeksios lakse anemi-virus vaksine
ATE115964T1 (de) Non-a non-b sequenzen.
ATE409705T1 (de) Pre-s-protein von hepatitis-b-virus (hbv) als adjuvans und komponente eines hbv-impfstoffs
WO2001092311A3 (fr) Bibliotheques peptidiques combinatoires convergentes et leur applicaton a la vaccination contre le virus de l'hepatite c
SE0002498D0 (sv) Papillomavirus vaccine
DE60142836D1 (de) Nicht menschliche tiermodelle die toleranz gegenüber hepatitis c virus immunogene aufweisen
DK1237571T3 (da) Toscana-virus-nukleinprotein
AU4394101A (en) A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus ORF2, and an antigenic polypeptide

Legal Events

Date Code Title Description
8364 No opposition during term of opposition